Structure Therapeutics (GPCR) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Perrigo (PRGO) over the past year, losing 9.8% versus a loss of 33.0%. Perrigo is the larger company by market cap ($2.01 billion vs $1.83 billion), about 1.1 times the size. Perrigo pays a dividend yielding 8.00%, while Structure Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | PRGO |
|---|---|---|
| Share price | $25.67 | $14.50 |
| Market cap | $1.83B | $2.01B |
| 1-day change | -3.79% | -0.34% |
| YTD return | -63.09% | +4.17% |
| 1-year return | -9.77% | -33.03% |
| 5-year return | — | -67.58% |
| Forward P/E | — | 6.05 |
| EPS (TTM) | $-3.03 | $-12.28 |
| Dividend yield | 0.00% | 8.00% |
| Annual dividend | $0.00 | $1.16 |
| 52-week high | $94.90 | $22.02 |
| 52-week low | $25.09 | $9.23 |
| Distance from 52-week high | -72.95% | -34.15% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +312.08% | +13.79% |
| Average volume | 965.00K | 2.80M |
| Shares outstanding | 71.31M | 138.37M |
| Employees | 281 | 8,100 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed PRGO by 23.3 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (8.00% vs 0.00%).
- The two companies sit in different sectors: Structure Therapeutics in Healthcare and Perrigo in Health Care.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
GPCR vs PRGO FAQ
Which is bigger, Structure Therapeutics or Perrigo?
Perrigo (PRGO) is larger, with a market capitalization of $2.01B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or PRGO?
GPCR returned -9.77% over the past 12 months, compared with -33.03% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Structure Therapeutics or Perrigo?
Perrigo pays a dividend yielding 8.00%, while Structure Therapeutics does not currently pay a regular dividend.
Are Structure Therapeutics and Perrigo in the same industry?
No. Structure Therapeutics is in the Healthcare sector, while Perrigo is in Health Care.